- About the hospital
- Case studies
- Designated Funds
- Patient & Family Support
- Research Grants
- What we have funded
- Your new hospital
Your support provides equipment, research and training but benefits individuals. To find out some of the stories behind the grants that University Hospital Birmingham Charities has provided read below.
Case Study 1 – Dion Morton grant
Professor Dion Morton received a grant of £60,951 from Queen Elizabeth Hospital Birmingham Charity towards his research into colorectal cancer
He explains “Colorectal cancer is the third most common malignancy in the world and is the second leading cause of cancer mortality. However, survival rates are good if the cancer can be detected at an early stage and surgically resected.
Pre-symptomatic screening of individuals between the ages of 50 and 65 has been proven to reduce mortality from colorectal cancer, but the current test we believe could be improved. The current screening test for colorectal cancer used in the NHS identifies 2% of the screening population as requiring further testing by colonoscopy.
50% of these subjects will receive a normal result and so would benefit if there was an alternative non-invasive test. We expect that our research will result in a reduction in the number of patients undergoing colonoscopy which is an invasive, expensive technique as we hope to develop a new test using DNA screening methods.
It is invaluable to have the funding from Queen Elizabeth Hospital Charity which will help us obtain the results needed if we are to take this forward to a national trial.”
Case Study 2 – Sarah Williams Williams grant
Dr Sarah Williams received a grant of £22,000 from Queen Elizabeth Hospital Birmingham Charity towards her research into treating lung cancer.
She explains “Lung cancer remains the leading cause of cancer deaths in the western world with over 30,000 people dying from the disease each year in the UK.
Approximately 80% of all lung cancers are of non-small cell histological type and the five year survival across all stages is around 12%. The majority of patients present with advanced inoperable disease and are thus candidates for palliative chemotherapy.
Current practice centres around the use of two drug combinations however, progress in terms of improved survival for patients with advanced non small cell lung cancer over recent years has been minimal.
My research is looking at whether adding a third modern chemotherapy drug derives further survival benefits for patients.
Queen Elizabeth Hospital Birmingham Charity is funding a pilot study to evaluate a novel three drug regimen containing cisplatin, docetaxel and pemetrexed in an attempt to identify a possible regimen that will be of benefit to patients and will only need to be administered once every three weeks.
This research would not be possible without the funding from the hospital charity.”Back to Why we need your help
“The hospital charity provides those added extras that make a huge difference to the lives of military patients and their families. Thank you for your support”
Royal Centre for Defence Medicine staff nurse